Valuation: Bioventix PLC

Market Cap 91.44M 125M 107M 99.89M 172M 11.92B 174M 1.18B 460M 5.99B 468M 458M 19.81B P/E 2026 *
13.1x
P/E 2027 * -
Enterprise Value 86.54M 118M 101M 94.54M 162M 11.29B 165M 1.12B 436M 5.67B 443M 433M 18.75B EV / Sales 2026 *
6.92x
EV / Sales 2027 * -
Free-Float
92.29%
Yield 2026 *
8.57%
Yield 2027 * -
1 day-2.78%
1 week+16.67%
Current month+15.89%
1 month+12.90%
3 months+6.06%
6 months+6.06%
Current year-8.14%
1 week 1,500
Extreme 1500
1,800
1 month 1,450
Extreme 1450
1,800
Current year 1,300
Extreme 1300
1,950
1 year 1,300
Extreme 1300
2,550
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 2003-12-22
Director of Finance/CFO 67 2020-06-30
Director TitleAgeSince
Director/Board Member 67 2010-11-24
Chairman 66 2004-10-31
Director/Board Member 67 2020-06-30
Date Insider Type Main position Quantity % Market Cap.
4/20/26 Free

Chief Financial Officer

9,967 0.1908%
11/26/25 Buy

Chief Financial Officer

150 0.0029%
11/4/25 Buy

Chief Executive Officer

875 0.0167%
Change 5-day change 1-year change 3-year change Capi.($)
-2.78%+16.67%-28.57%-53.95% 128M
+1.09%+5.26%+4.44%+26.03% 51.22B
-1.07%+2.82%+474.18%+601.24% 45.38B
+1.47%+9.79%+40.15%+21.21% 42.15B
+1.44%+7.77%+19.27%+90.94% 41.97B
-0.93%-4.33%+17.87%+51.96% 31.95B
+1.32%+7.30%+36.93%+152.36% 17.1B
-0.60%+1.93% - - 16.73B
+0.03%+3.41%+7.12%+35.49% 14.76B
+1.28%+5.41%+91.01%+46.93% 13.91B
Average +0.13%+4.98%+73.60%+108.02% 27.53B
Weighted average by Cap. +0.47%+3.56%+103.72%+149.92%

Financials

2026 *2027 *
Net sales 12.5M 17.04M 14.59M 13.66M 23.46M 1.63B 23.77M 161M 62.92M 819M 63.97M 62.58M 2.71B -
Net income 7.11M 9.69M 8.3M 7.77M 13.35M 927M 13.52M 91.79M 35.8M 466M 36.4M 35.61M 1.54B -
Net Debt -4.89M -6.67M -5.71M -5.35M -9.18M -638M -9.31M -63.17M -24.63M -321M -25.05M -24.5M -1.06B -
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
26-08-21 GBX 1,750.00 -2.78% 8,840
26-08-20 GBX 1,800.00 +7.46% 8,822
26-08-19 GBX 1,675.00 +6.35% 8,286
26-08-18 GBX 1,575.00 +1.61% 4,579
26-08-17 GBX 1,550.00 +3.33% 11,290
Trader
Investor
Global
-
Quality
ESG MSCI
CCC

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BVXP Stock